ServiceUpdated on 13 August 2025
Viral Vector Development & Manufacturing
About
There is no one-size-fits-all solution for viral vector manufacturing. Just like the therapy you are developing, you require a tailored approach. NecstGen offers a wide range of services and expert professionals to support you with that.
Development:
-
Translational activities to create GMP compliant manufacturing
-
Process design and optimisation
-
Scale-up to clinically relevant volumes
-
Automation and closed processes
Manufacturing:
-
Pre-clinical or toxicology study material
-
Phase I to Phase III clinical trial material
Viral Vector:
-
Lentiviruses (LV)
-
Adeno-associated viruses (AAV)
-
Oncolytic viruses
-
Exosomes and Extracellular Vesicles (EVs)
-
Others
We will be happy to discuss and help you bring your cell therapies to patients.
Type
- Development
- Manufacturing
Applies to
- Innovative therapies - Gene therapy
- Innovative therapies - Oncolytic viruses
Similar opportunities
Service
Cell Therapy Development & Manufacturing
- Development
- Manufacturing
- Innovative therapies - Gene editing
- Innovative therapies - Stem cell therapy
- Innovative therapies - Immune cell therapy
- Innovative therapies - Somatic cell therapy
- Innovative therapies - Tissue engineered products
Sophia Kolbe
Business Developer at NecstGen
Leiden, Netherlands
Service
Benefits of decentralized independent drug development for patients
- Others
- Development
- Innovative therapies - Gene editing
- Innovative therapies - Stem cell therapy
Marco Traub
CEO/CSO at TheSwissClinic-Society
Berne, Switzerland
Project cooperation
Neo-adjuvant oncolytic immune activator
Wenliang Dong
CEO at ORCA Therapeutics BV
Amsterdam, Netherlands